title: Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.
abstract: The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
authors: Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA. becke021@mc.duke.edu
authors: Richard C
authors: RC
authors: Becker
authors: James
authors: J
authors: Scheiman
authors: Harold L
authors: HL
authors: Dauerman
authors: Frederick
authors: F
authors: Spencer
authors: Sunil
authors: S
authors: Rao
authors: Marc
authors: M
authors: Sabatine
authors: David A
authors: DA
authors: Johnson
authors: Frances
authors: F
authors: Chan
authors: Neena S
authors: NS
authors: Abraham
authors: Eamonn M M
authors: EM
authors: Quigley
mesh_terms: D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects; D006470:Hemorrhage / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000209:etiology
chemical_list: D010975:Platelet Aggregation Inhibitors